melatonin has been researched along with Osteoporosis in 50 studies
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Little is known about the implications of circRNAs in the effects of melatonin (MEL) on bone marrow mesenchymal stem cell (BMSC) osteogenic differentiation and osteoporosis (OP) progression." | 8.02 | Melatonin promotes bone marrow mesenchymal stem cell osteogenic differentiation and prevents osteoporosis development through modulating circ_0003865 that sponges miR-3653-3p. ( Chen, T; Chen, Y; Deng, Z; Gao, B; Gao, W; Huang, D; Liang, A; Liang, T; Liang, Z; Peng, Y; Qiu, J; Qiu, X; Su, P; Wang, X; Wu, Z; Xu, C; Zhou, H; Zhu, Y, 2021) |
| "The protective effect of melatonin against bone metabolism imbalance in osteoporosis (OP) induced by drugs such as retinoic acid (RA) is unclear." | 7.91 | Melatonin prevents bone destruction in mice with retinoic acid-induced osteoporosis. ( Gao, B; Huang, D; Li, Y; Lian, C; Liang, A; Liang, T; Liao, Z; Peng, Y; Qiu, J; Qiu, X; Su, P; Wang, X; Xu, C; Yang, X; Zhou, H; Zhu, Y, 2019) |
| "The anti-catabolic bisphosphonate alendronate is considered as the first-line medical treatment in post-menopausal osteoporosis; but several side effects, including gastric mucosal injury, are associated with its use." | 7.91 | Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats. ( Akkiprik, M; Çilingir-Kaya, ÖT; Ercan, F; Gürler, EB; Peker Eyüboglu, I; Reiter, RJ; Yegen, BÇ, 2019) |
| " Serum levels of melatonin decrease in MS patients who are also at risk of osteoporosis." | 7.88 | Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis. ( Arnoult, D; Farhadi, N; Ghareghani, M; Scavo, L; Zibara, K, 2018) |
| "Both aero-bic exercise and melatonin can improve diabetic osteoporosis, and the effect of both joint intervention is more significant, it may be associated with oxidative stress by increasing the ability of diabetic rats, regulate glucose metabolism in order to effectively reduce the calcium and PTH, improve BMD to alleviate osteoporosis." | 7.85 | [Effects of aerobic exercise combined with melatonin on osteoporosis of type II diabetic rats]. ( Jing, HF; Wang, XM, 2017) |
| "To analyze histomorphometric, densitometric and biochemical effects of melatonin on osteoporosis in ovariectomized rats." | 7.74 | Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats. ( Başdemir, G; Oktem, G; Tanyalçin, T; Uslu, S; Uysal, A; Yurtseven, M, 2007) |
| "There have been suggestions in literature that characteristic changes of bone mass in osteoporosis may be related to the melatonin (Mel): The aim of this study was to demonstrate whether pinealectomy and Mel administration can affect postmenopausal osteoporosis processes induced in female rats by way of ovariectomy." | 7.71 | The influence of pinealectomy and melatonin administration on the dynamic pattern of biochemical markers of bone metabolism in experimental osteoporosis in the rat. ( Kajdaniuk, D; Kos-Kudla, B; Marek, B; Ostrowska, Z; Staszewicz, P; Strzelczyk, J; Szapska, B, 2002) |
| "Melatonin is a signal molecule that modulates the biological circadian rhythms of vertebrates." | 6.61 | Melatonin: Another avenue for treating osteoporosis? ( Hu, W; Jiang, S; Li, T; Lu, C; Xin, Z; Yang, W; Yang, Y; Yang, Z, 2019) |
| "Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms." | 6.53 | Melatonin as a Potential Agent in the Treatment of Sarcopenia. ( Boga, JA; Coto-Montes, A; Reiter, RJ; Tan, DX, 2016) |
| "Melatonin is a neurohormone secreted mainly by the pineal gland that controls circadian rhythm, which is primarily regulated by light." | 6.52 | Melatonin in aging women. ( Caglar, GS; Gursoy, AY; Kiseli, M, 2015) |
| "In particular, its use in cancer prevention, osteoporosis and, as an adjuvant to other therapies are discussed." | 6.43 | Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. ( Davis, VL; Doctor, JS; Radio, NM; Witt-Enderby, PA, 2006) |
| "Melatonin has shown positive effects on osteoblast differentiation and bone formation; however, it was unknown whether melatonin could restore OP-impaired osteogenic potential of BMMSCs and what the underlying mechanisms entailed." | 5.56 | Melatonin restores the osteoporosis-impaired osteogenic potential of bone marrow mesenchymal stem cells by preserving SIRT1-mediated intracellular antioxidant properties. ( Chen, AC; Chen, W; Chen, X; He, F; Liu, T; Pan, G; Pei, M; Shi, Q; Yang, H, 2020) |
| "Type 2 diabetes mellitus is often complicated by osteoporosis, a process which may involve osteoblast autophagy." | 5.43 | Melatonin suppresses autophagy in type 2 diabetic osteoporosis. ( Liu, F; Liu, JH; Meng, HZ; Shi, PX; Sun, GH; Yang, B; Yang, MW; Yang, RF; Zhang, WL, 2016) |
| "A systematic search of PubMed, Embase, and Scielo databases was performed, looking for articles on Melatonin and rheumatic diseases published between 1966 and August 2022." | 5.41 | Melatonin supplementation improves rheumatological disease activity: A systematic review. ( de Carvalho, JF; Skare, TL, 2023) |
| "The findings demonstrated that melatonin has beneficial effect in bone- and cartilage-related disorders such as osteoporosis, bone fracture healing, osteoarthritis, and rheumatoid arthritis, in addition to the control of sleep and circadian rhythms." | 5.41 | Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects. ( Bagherifard, A; Hosseinzadeh, A; Karimi-Behnagh, A; Koosha, F; Mehrzadi, S; Reiter, RJ; Sheibani, M, 2023) |
| "Rats treated with melatonin had higher bone volume, bone trabecular number, trabecular thickness, and cortical thickness in comparison to the control group." | 5.40 | Melatonin dietary supplement as an anti-aging therapy for age-related bone loss. ( Barralet, JE; Calvo-Guirado, JL; Eimar, H; Prieto, S; Tamimi, F; Torres, J; Tresguerres, IF; Tresguerres, JA, 2014) |
| " Melatonin has demonstrated a beneficial effect on bone metabolism with the potential to treat fractures, bone defects and osteoporosis." | 5.22 | Melatonin having Therapeutic Bone Regenerating Capacity in Biomaterials. ( He, C; Huang, J; Li, Y, 2022) |
| "Leptin or melatonin improved Sema4d's role in trabecular bone microstructure, bone production, and repairment of trabecular bone loss in osteoporosis rats." | 4.31 | Impact of leptin or melatonin on Sema4D overexpression-related bone metabolism. ( Chen, X; Li, Z; Lin, X; Lin, Y; Lin, Z; Xie, D; Xiong, S, 2023) |
| "In rats with osteoporosis, leptin and melatonin can be seen to augment the trabecular microstructure of the bone, augment bone growth, diminish trabecular harm, and mend the bone." | 4.31 | Leptin and melatonin's effects on OVX rodents' bone metabolism. ( Li, Z; Lin, Y; Lin, Z; Xiong, S; Yu, G, 2023) |
| "Previous studies have revealed that melatonin could play a role in anti-osteoporosis and promoting osteogenesis." | 4.12 | Melatonin Accelerates Osteoporotic Bone Defect Repair by Promoting Osteogenesis-Angiogenesis Coupling. ( Feng, Z; Li, J; Li, Y; Liao, L; Yang, H; Zheng, S; Zhou, C, 2022) |
| "Little is known about the implications of circRNAs in the effects of melatonin (MEL) on bone marrow mesenchymal stem cell (BMSC) osteogenic differentiation and osteoporosis (OP) progression." | 4.02 | Melatonin promotes bone marrow mesenchymal stem cell osteogenic differentiation and prevents osteoporosis development through modulating circ_0003865 that sponges miR-3653-3p. ( Chen, T; Chen, Y; Deng, Z; Gao, B; Gao, W; Huang, D; Liang, A; Liang, T; Liang, Z; Peng, Y; Qiu, J; Qiu, X; Su, P; Wang, X; Wu, Z; Xu, C; Zhou, H; Zhu, Y, 2021) |
| "The protective effect of melatonin against bone metabolism imbalance in osteoporosis (OP) induced by drugs such as retinoic acid (RA) is unclear." | 3.91 | Melatonin prevents bone destruction in mice with retinoic acid-induced osteoporosis. ( Gao, B; Huang, D; Li, Y; Lian, C; Liang, A; Liang, T; Liao, Z; Peng, Y; Qiu, J; Qiu, X; Su, P; Wang, X; Xu, C; Yang, X; Zhou, H; Zhu, Y, 2019) |
| "The anti-catabolic bisphosphonate alendronate is considered as the first-line medical treatment in post-menopausal osteoporosis; but several side effects, including gastric mucosal injury, are associated with its use." | 3.91 | Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats. ( Akkiprik, M; Çilingir-Kaya, ÖT; Ercan, F; Gürler, EB; Peker Eyüboglu, I; Reiter, RJ; Yegen, BÇ, 2019) |
| " Serum levels of melatonin decrease in MS patients who are also at risk of osteoporosis." | 3.88 | Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis. ( Arnoult, D; Farhadi, N; Ghareghani, M; Scavo, L; Zibara, K, 2018) |
| "Both aero-bic exercise and melatonin can improve diabetic osteoporosis, and the effect of both joint intervention is more significant, it may be associated with oxidative stress by increasing the ability of diabetic rats, regulate glucose metabolism in order to effectively reduce the calcium and PTH, improve BMD to alleviate osteoporosis." | 3.85 | [Effects of aerobic exercise combined with melatonin on osteoporosis of type II diabetic rats]. ( Jing, HF; Wang, XM, 2017) |
| "To analyze histomorphometric, densitometric and biochemical effects of melatonin on osteoporosis in ovariectomized rats." | 3.74 | Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats. ( Başdemir, G; Oktem, G; Tanyalçin, T; Uslu, S; Uysal, A; Yurtseven, M, 2007) |
| "There have been suggestions in literature that characteristic changes of bone mass in osteoporosis may be related to the melatonin (Mel): The aim of this study was to demonstrate whether pinealectomy and Mel administration can affect postmenopausal osteoporosis processes induced in female rats by way of ovariectomy." | 3.71 | The influence of pinealectomy and melatonin administration on the dynamic pattern of biochemical markers of bone metabolism in experimental osteoporosis in the rat. ( Kajdaniuk, D; Kos-Kudla, B; Marek, B; Ostrowska, Z; Staszewicz, P; Strzelczyk, J; Szapska, B, 2002) |
| "Melatonin is a pharmaceutical ingredient in numerous medicines, over-the-counter medicines, nutraceuticals, and dietary supplements, which benefit disease prevention and treatment, including osteoporosis and neurodegenerative diseases." | 2.72 | Melatonin in neuroskeletal biology. ( O'Brien, M; Patel, A; Wang, X; Zhou, EW; Zhou, S, 2021) |
| "Melatonin is a signal molecule that modulates the biological circadian rhythms of vertebrates." | 2.61 | Melatonin: Another avenue for treating osteoporosis? ( Hu, W; Jiang, S; Li, T; Lu, C; Xin, Z; Yang, W; Yang, Y; Yang, Z, 2019) |
| "Melatonin is a neurohormone associated with sleep and wakefulness and is mainly produced by the pineal gland." | 2.61 | The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health. ( Aly, H; Bhattacharya, P; Chiocca, EA; Cui, Y; Fu, J; Jiang, J; Johnson, MD; Lawler, SE; Liu, Y; Luo, C; Ma, H; Reiter, RJ; Rozental, R; Wang, X; Yang, H; Yang, Q; Yao, J; Zhang, X; Zhou, S, 2019) |
| "Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms." | 2.53 | Melatonin as a Potential Agent in the Treatment of Sarcopenia. ( Boga, JA; Coto-Montes, A; Reiter, RJ; Tan, DX, 2016) |
| "Melatonin is a neurohormone secreted mainly by the pineal gland that controls circadian rhythm, which is primarily regulated by light." | 2.52 | Melatonin in aging women. ( Caglar, GS; Gursoy, AY; Kiseli, M, 2015) |
| "Melatonin is an endogenous hormone rhythmically produced in the pineal gland under the control of the suprachiasmatic nucleus (SCN) and the light/dark cycle." | 2.49 | Melatonin effects on hard tissues: bone and tooth. ( He, HW; Huang, F; Liu, J, 2013) |
| "Bone resorption is reduced by increased synthesis of osteoprogeterin (OPG), a decoy receptor that prevents receptor activator of NK-κB ligand (RANKL) in binding to its receptor." | 2.49 | Melatonin and the skeleton. ( Amstrup, AK; Mosekilde, L; Rejnmark, L; Sikjaer, T, 2013) |
| "Melatonin is a hormone with indolaminic structure, produced in the pineal gland during darkness, with chronobiological activity that has been known for decades." | 2.44 | [Melatonina: old molecule, new medicament]. ( Fernández-Tresguerres Hernández, JA, 2008) |
| "In particular, its use in cancer prevention, osteoporosis and, as an adjuvant to other therapies are discussed." | 2.43 | Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. ( Davis, VL; Doctor, JS; Radio, NM; Witt-Enderby, PA, 2006) |
| "Diabetic osteoporosis is secondary osteoporosis and a serious complication of diabetes with a high incidence rate and poor prognosis." | 1.72 | Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts. ( Ming, J; Tian, Y, 2022) |
| "The typical symptoms of patients with Alzheimer's disease (AD) are amyloid-β (Aβ) plaques and tau hyperphosphorylation." | 1.72 | Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer's Disease. ( Tsai, YL; Wang, YF; Yen, CT, 2022) |
| "Melatonin has shown positive effects on osteoblast differentiation and bone formation; however, it was unknown whether melatonin could restore OP-impaired osteogenic potential of BMMSCs and what the underlying mechanisms entailed." | 1.56 | Melatonin restores the osteoporosis-impaired osteogenic potential of bone marrow mesenchymal stem cells by preserving SIRT1-mediated intracellular antioxidant properties. ( Chen, AC; Chen, W; Chen, X; He, F; Liu, T; Pan, G; Pei, M; Shi, Q; Yang, H, 2020) |
| "Osteoporosis is closely associated with the dysfunction of bone metabolism, which is caused by the imbalance between new bone formation and bone resorption." | 1.51 | MicroRNA-92b-5p modulates melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ICAM-1. ( Bamba, D; Bi, Z; Cai, B; Ding, F; Feng, C; Fu, Y; Gao, M; Gong, R; He, M; Huang, Q; Jin, M; Li, Y; Liu, T; Ma, W; Reiters, R; Sukhareva, N; Sun, Y; Xu, C; Yan, G; Yang, F; Yang, L; Yuan, Y; Zhang, L, 2019) |
| "Type 2 diabetes mellitus is often complicated by osteoporosis, a process which may involve osteoblast autophagy." | 1.43 | Melatonin suppresses autophagy in type 2 diabetic osteoporosis. ( Liu, F; Liu, JH; Meng, HZ; Shi, PX; Sun, GH; Yang, B; Yang, MW; Yang, RF; Zhang, WL, 2016) |
| "Rats treated with melatonin had higher bone volume, bone trabecular number, trabecular thickness, and cortical thickness in comparison to the control group." | 1.40 | Melatonin dietary supplement as an anti-aging therapy for age-related bone loss. ( Barralet, JE; Calvo-Guirado, JL; Eimar, H; Prieto, S; Tamimi, F; Torres, J; Tresguerres, IF; Tresguerres, JA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (24.00) | 29.6817 |
| 2010's | 19 (38.00) | 24.3611 |
| 2020's | 19 (38.00) | 2.80 |
| Authors | Studies |
|---|---|
| MacDonald, IJ | 1 |
| Tsai, HC | 1 |
| Chang, AC | 1 |
| Huang, CC | 1 |
| Yang, SF | 1 |
| Tang, CH | 1 |
| Patel, A | 1 |
| Zhou, EW | 1 |
| O'Brien, M | 1 |
| Wang, X | 4 |
| Zhou, S | 2 |
| Chen, W | 2 |
| Lv, N | 1 |
| Liu, H | 2 |
| Gu, C | 1 |
| Zhou, X | 1 |
| Qin, W | 1 |
| Chen, AC | 2 |
| Chen, L | 2 |
| Yang, H | 5 |
| Chen, X | 3 |
| Liu, T | 3 |
| He, F | 2 |
| Liu, HD | 2 |
| Ren, MX | 2 |
| Li, Y | 5 |
| Zhang, RT | 1 |
| Ma, NF | 1 |
| Li, TL | 2 |
| Jiang, WK | 2 |
| Zhou, Z | 2 |
| Yao, XW | 1 |
| Liu, ZY | 1 |
| Yang, M | 2 |
| Zheng, S | 1 |
| Zhou, C | 1 |
| Li, J | 1 |
| Feng, Z | 1 |
| Liao, L | 2 |
| Tsai, YL | 1 |
| Yen, CT | 1 |
| Wang, YF | 1 |
| Tian, Y | 1 |
| Ming, J | 1 |
| Li, F | 2 |
| Lun, D | 1 |
| Liu, D | 1 |
| Jia, Z | 1 |
| Zhu, Z | 1 |
| Liu, Z | 1 |
| Li, X | 1 |
| Lin, Z | 2 |
| Xiong, S | 2 |
| Lin, Y | 2 |
| Li, Z | 2 |
| Xie, D | 1 |
| Lin, X | 2 |
| de Carvalho, JF | 1 |
| Skare, TL | 1 |
| Bagherifard, A | 1 |
| Hosseinzadeh, A | 1 |
| Koosha, F | 1 |
| Sheibani, M | 1 |
| Karimi-Behnagh, A | 1 |
| Reiter, RJ | 7 |
| Mehrzadi, S | 1 |
| Yu, G | 1 |
| Liang, T | 2 |
| Zhu, Y | 2 |
| Qiu, J | 2 |
| Qiu, X | 2 |
| Lian, C | 1 |
| Gao, B | 2 |
| Peng, Y | 2 |
| Liang, A | 2 |
| Zhou, H | 2 |
| Yang, X | 1 |
| Liao, Z | 1 |
| Xu, C | 3 |
| Su, P | 2 |
| Huang, D | 2 |
| Shi, Q | 1 |
| Pan, G | 1 |
| Pei, M | 1 |
| Xiao, L | 1 |
| Lin, J | 1 |
| Chen, R | 1 |
| Huang, Y | 1 |
| Liu, Y | 2 |
| Bai, J | 1 |
| Ge, G | 1 |
| Shi, X | 1 |
| Chen, Y | 2 |
| Shi, J | 1 |
| Aiqing, L | 1 |
| Geng, D | 1 |
| Wang, Z | 1 |
| Chen, T | 1 |
| Deng, Z | 2 |
| Gao, W | 1 |
| Wu, Z | 1 |
| Liang, Z | 1 |
| Lu, X | 1 |
| Yu, S | 1 |
| Chen, G | 1 |
| Zheng, W | 1 |
| Peng, J | 1 |
| Huang, X | 1 |
| Huang, J | 1 |
| He, C | 1 |
| Han, H | 1 |
| Tian, T | 1 |
| Huang, G | 1 |
| Li, D | 1 |
| Yang, S | 1 |
| Ghareghani, M | 1 |
| Scavo, L | 1 |
| Arnoult, D | 1 |
| Zibara, K | 1 |
| Farhadi, N | 1 |
| Jing, HF | 1 |
| Wang, XM | 1 |
| Luo, C | 1 |
| Yang, Q | 1 |
| Jiang, J | 1 |
| Bhattacharya, P | 1 |
| Cui, Y | 1 |
| Ma, H | 1 |
| Yao, J | 1 |
| Lawler, SE | 1 |
| Zhang, X | 2 |
| Fu, J | 1 |
| Rozental, R | 1 |
| Aly, H | 1 |
| Johnson, MD | 1 |
| Chiocca, EA | 1 |
| Song, C | 1 |
| Wang, J | 1 |
| Kim, B | 1 |
| Lu, C | 2 |
| Zhang, Z | 1 |
| Kang, H | 1 |
| Sun, Y | 2 |
| Guan, H | 1 |
| Fang, Z | 1 |
| Li, T | 1 |
| Jiang, S | 1 |
| Yang, W | 1 |
| Yang, Z | 1 |
| Hu, W | 1 |
| Xin, Z | 1 |
| Yang, Y | 1 |
| Gürler, EB | 1 |
| Çilingir-Kaya, ÖT | 1 |
| Peker Eyüboglu, I | 1 |
| Ercan, F | 1 |
| Akkiprik, M | 1 |
| Yegen, BÇ | 1 |
| Feng, C | 1 |
| Gao, M | 1 |
| Jin, M | 1 |
| Yuan, Y | 1 |
| Yan, G | 1 |
| Gong, R | 1 |
| He, M | 1 |
| Fu, Y | 1 |
| Zhang, L | 1 |
| Huang, Q | 1 |
| Ding, F | 1 |
| Ma, W | 1 |
| Bi, Z | 1 |
| Sukhareva, N | 1 |
| Bamba, D | 1 |
| Reiters, R | 1 |
| Yang, F | 1 |
| Cai, B | 1 |
| Yang, L | 1 |
| Liu, J | 1 |
| Huang, F | 1 |
| He, HW | 1 |
| Amstrup, AK | 1 |
| Sikjaer, T | 1 |
| Mosekilde, L | 1 |
| Rejnmark, L | 1 |
| Tresguerres, IF | 1 |
| Tamimi, F | 1 |
| Eimar, H | 1 |
| Barralet, JE | 1 |
| Prieto, S | 1 |
| Torres, J | 1 |
| Calvo-Guirado, JL | 1 |
| Tresguerres, JA | 1 |
| Litovka, IH | 1 |
| Mazepa-Kryzhanivs'ka, YO | 1 |
| Berezovskyĭ, VIa | 1 |
| Arushanian, ÉB | 1 |
| Gursoy, AY | 1 |
| Kiseli, M | 1 |
| Caglar, GS | 1 |
| Zhang, WL | 1 |
| Meng, HZ | 1 |
| Yang, RF | 1 |
| Yang, MW | 1 |
| Sun, GH | 1 |
| Liu, JH | 1 |
| Shi, PX | 1 |
| Liu, F | 1 |
| Yang, B | 1 |
| Shuai, Y | 1 |
| Su, X | 1 |
| Yu, Y | 1 |
| Shao, B | 1 |
| Jing, H | 1 |
| Jin, Y | 1 |
| Coto-Montes, A | 1 |
| Boga, JA | 1 |
| Tan, DX | 3 |
| Suzuki, N | 1 |
| Somei, M | 1 |
| Seki, A | 1 |
| Hattori, A | 1 |
| Fernández-Tresguerres Hernández, JA | 1 |
| Egermann, M | 1 |
| Gerhardt, C | 1 |
| Barth, A | 1 |
| Maestroni, GJ | 1 |
| Schneider, E | 1 |
| Alini, M | 1 |
| Kotlarczyk, MP | 1 |
| Lassila, HC | 1 |
| O'Neil, CK | 1 |
| D'Amico, F | 1 |
| Enderby, LT | 1 |
| Witt-Enderby, PA | 2 |
| Balk, JL | 1 |
| Cardinali, DP | 1 |
| Ladizesky, MG | 1 |
| Boggio, V | 1 |
| Cutrera, RA | 1 |
| Mautalen, C | 1 |
| Turgut, M | 1 |
| Uslu, S | 3 |
| Uysal, A | 3 |
| Yurtseven, ME | 2 |
| Ustün, H | 1 |
| Oktem, G | 2 |
| Vatansever, SH | 1 |
| Aktug, H | 1 |
| Radio, NM | 1 |
| Doctor, JS | 1 |
| Davis, VL | 1 |
| Ostrowska, Z | 2 |
| Wołkowska-Pokrywa, K | 1 |
| Kos-Kudła, B | 1 |
| Swietochowska, E | 1 |
| Marek, B | 2 |
| Kajdaniuk, D | 2 |
| Sanchez-Hidalgo, M | 1 |
| Lu, Z | 1 |
| Maldonado, MD | 1 |
| Gregerman, RI | 1 |
| Yurtseven, M | 1 |
| Tanyalçin, T | 1 |
| Başdemir, G | 1 |
| Manchester, LC | 1 |
| Pilar Terron, M | 1 |
| Flores, LJ | 1 |
| Koppisepi, S | 1 |
| Mead, MN | 1 |
| Kos-Kudla, B | 1 |
| Staszewicz, P | 1 |
| Szapska, B | 1 |
| Strzelczyk, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women[NCT01152580] | Phase 1 | 19 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The mean change in bone mineral density (BMD), represented by T-scores, was assessed by calcaneal ultrasound in women taking melatonin (3 mg) or placebo nightly at baseline and after 6 months. A T-score is a comparison of a subject's BMD to that of a healthy 30 year old female of the same ethnicity. The more negative the T-score, the worse the BMD. Osteoporosis or brittle bone disease is defined as a T-score -2.5 or less. A more negative mean change in a T-score would indicate a worsening of BMD. A more positive mean change in a T-score would indicate an improvement of BMD. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | T-score (Mean) |
|---|---|
| Sugar Pill | -0.02 |
| Melatonin | 0.05 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | 0.1 |
| Melatonin | -0.6 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.2 |
| Melatonin | -0.4 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.7 |
| Melatonin | -0.4 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.2 |
| Melatonin | 0.4 |
Osteocalcin is a measure of osteoblast activity because it is secreted from osteoblasts. Osteocalcin levels were measured in the serum of women at baseline and after 6 months of taking placebo or melatonin (3 mg) and the data are reported as ng/mL. Osteoblasts are bone-forming cells so a more positive mean change in osteoblast activity over time (6 months - baseline) could indicate an improvement in bone mineral density. A more negative mean change in osteocalcin levels over time (6 months - baseline) could indicate a worsening of bone mineral density. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | ng/mL (Mean) |
|---|---|
| Sugar Pill | -0.6 |
| Melatonin | 1.83 |
Type-1 collagen cross-linked N-telopeptide (NTX) levels were measured in the serum of women at baseline and after taking placebo or melatonin (3 mg) nightly for 6 months. NTX, reported as bone collagen equivalents (BCE), is released from bone due to the actions of osteoclasts or bone breakdown cells. A more positive mean change in NTX levels (6 months - baseline) could result in a worsening of bone mineral density due to an increase in bone breakdown whereas a more negative mean change in NTX levels could result in an improvement in bone mineral density due to a decrease in bone breakdown. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | nM BCE (Mean) |
|---|---|
| Sugar Pill | -0.36 |
| Melatonin | -0.32 |
"Pittsburgh Sleep Quality Index (PSQI) Questionnaire is a validated questionnaire that assesses the quality and quantity of sleep and sleep disorders.This survey is designed to identify good and poor sleepers and has a score scale that ranges from 0-21 with 0 being good quality of sleep and 21 being poor quality of sleep and/or indicating as having a sleep disorder. A more positive mean change in the PSQI over time indicates a worsening of sleep. A more negative mean change in the PSQI over time indicates an improvement in sleep." (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -1.0 |
| Melatonin | -0.5 |
21 reviews available for melatonin and Osteoporosis
| Article | Year |
|---|---|
Melatonin Inhibits Osteoclastogenesis and Osteolytic Bone Metastasis: Implications for Osteoporosis.
Topics: Animals; Antioxidants; Bone Neoplasms; Humans; Melatonin; Osteoclasts; Osteogenesis; Osteoporosis | 2021 |
Melatonin in neuroskeletal biology.
Topics: Aged; Biology; Humans; Melatonin; Osteoporosis; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2021 |
Melatonin supplementation improves rheumatological disease activity: A systematic review.
Topics: Arthritis, Rheumatoid; Dietary Supplements; Fibromyalgia; Humans; Melatonin; Osteoarthritis; Osteopo | 2023 |
Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects.
Topics: Animals; Bone and Bones; Circadian Rhythm; Melatonin; Osteoporosis; Sleep | 2023 |
Insight into the roles of melatonin in bone tissue and bone‑related diseases (Review).
Topics: Animals; Bone and Bones; Dose-Response Relationship, Drug; Female; Humans; Melatonin; Osteoarthritis | 2021 |
Melatonin having Therapeutic Bone Regenerating Capacity in Biomaterials.
Topics: Biocompatible Materials; Bone Regeneration; Humans; Melatonin; Osteogenesis; Osteoporosis | 2022 |
The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health.
Topics: Animals; Brain Injuries; Humans; Liver Diseases; Melatonin; Neuroprotective Agents; Osteoporosis; Ox | 2019 |
Insights into the Role of Circadian Rhythms in Bone Metabolism: A Promising Intervention Target?
Topics: Animals; Bone and Bones; Circadian Clocks; Circadian Rhythm; Homeostasis; Humans; Melatonin; Osteopo | 2018 |
Melatonin: Another avenue for treating osteoporosis?
Topics: Animals; Bone and Bones; Humans; Melatonin; Osteoporosis | 2019 |
Melatonin effects on hard tissues: bone and tooth.
Topics: Animals; Bone and Bones; Bone Remodeling; Dental Implants; Humans; Melatonin; Osteoporosis; Tooth | 2013 |
Melatonin and the skeleton.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Circadian Rhythm; Diseas | 2013 |
[The effect of melatonin on bone tissue metabolism].
Topics: Aging; Animals; Bone and Bones; Circadian Rhythm; Humans; Melatonin; Mice; Osteoblasts; Osteogenesis | 2014 |
[Melatonin participates in the origin and limitation of bone pathohological processes].
Topics: Aging; Animals; Bone and Bones; Fractures, Bone; Gene Expression Regulation; Humans; Melatonin; Oste | 2015 |
Melatonin in aging women.
Topics: Aging; Animals; Carbohydrate Metabolism; Female; Humans; Lipid Metabolism; Melatonin; Menopause; Neo | 2015 |
Melatonin as a Potential Agent in the Treatment of Sarcopenia.
Topics: Aging; Animals; Antioxidants; Humans; Melatonin; Muscle, Skeletal; Osteoporosis; Sarcopenia | 2016 |
Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases.
Topics: Animals; Bone Density; Bone Diseases; Bone Matrix; Calcium, Dietary; Diaphyses; Goldfish; Melatonin; | 2008 |
[Melatonina: old molecule, new medicament].
Topics: Administration, Oral; Age Factors; Aged; Alzheimer Disease; Animals; Antioxidants; Central Nervous S | 2008 |
Melatonin effects on bone: experimental facts and clinical perspectives.
Topics: Aged; Animals; Bone Development; Female; Growth Hormone; Humans; Melatonin; Osteoporosis | 2003 |
Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy.
Topics: Animals; Chemotherapy, Adjuvant; Humans; Melatonin; Neoplasms; Osteoporosis; Receptors, Melatonin; S | 2006 |
[Melatonin and bone status].
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Female; Humans; Melatonin; Osteoblasts; Oste | 2006 |
Medical implications of melatonin: receptor-mediated and receptor-independent actions.
Topics: Animals; Antioxidants; Cataract; Free Radicals; Humans; Hyperoxia; Hyperthyroidism; Melatonin; Model | 2007 |
1 trial available for melatonin and Osteoporosis
| Article | Year |
|---|---|
Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women.
Topics: Analysis of Variance; Blood Pressure; Bone Density; Collagen Type I; Double-Blind Method; Female; Hu | 2012 |
28 other studies available for melatonin and Osteoporosis
| Article | Year |
|---|---|
Melatonin Improves the Resistance of Oxidative Stress-Induced Cellular Senescence in Osteoporotic Bone Marrow Mesenchymal Stem Cells.
Topics: Animals; Antioxidants; Cellular Senescence; Female; Melatonin; Mesenchymal Stem Cells; Osteoporosis; | 2022 |
Melatonin alleviates hydrogen peroxide induced oxidative damage in MC3T3-E1 cells and promotes osteogenesis by activating SIRT1.
Topics: Animals; Hydrogen Peroxide; Melatonin; Osteoblasts; Osteogenesis; Osteoporosis; Oxidative Stress; Ra | 2022 |
Melatonin Accelerates Osteoporotic Bone Defect Repair by Promoting Osteogenesis-Angiogenesis Coupling.
Topics: Animals; Cell Differentiation; Melatonin; Osteogenesis; Osteoporosis; Rats; Vascular Endothelial Gro | 2022 |
Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Astrocytes; Calcium; Humans; Ions; Melatonin; Osteoporosis | 2022 |
Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts.
Topics: Cell Differentiation; Glucose; Humans; Ligands; Melatonin; Osteoblasts; Osteoclasts; Osteogenesis; O | 2022 |
Melatonin activates mitochondrial unfolded protein response to preserve osteogenic potential of senescent BMSCs via upregulating PDI-6.
Topics: Aging; Animals; beta Catenin; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Melatonin; M | 2023 |
Daytime administration of melatonin has better protective effects on bone loss in ovariectomized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Female; Femur; Humans; Melatonin; Osteoporosis; Ova | 2023 |
Impact of leptin or melatonin on Sema4D overexpression-related bone metabolism.
Topics: Animals; Bone Density; Female; Humans; Leptin; Melatonin; Osteoporosis; Ovariectomy; Rats; Rats, Spr | 2023 |
Leptin and melatonin's effects on OVX rodents' bone metabolism.
Topics: Animals; Bone Density; Leptin; Melatonin; Osteoporosis; Rats; Rats, Sprague-Dawley; Rodentia; Tartra | 2023 |
Melatonin prevents bone destruction in mice with retinoic acid-induced osteoporosis.
Topics: Alkaline Phosphatase; Animals; Bone Remodeling; Cancellous Bone; Female; Femur; Melatonin; Mice; Ost | 2019 |
Melatonin restores the osteoporosis-impaired osteogenic potential of bone marrow mesenchymal stem cells by preserving SIRT1-mediated intracellular antioxidant properties.
Topics: Animals; Antioxidants; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Female; Humans; Mel | 2020 |
Sustained Release of Melatonin from GelMA Liposomes Reduced Osteoblast Apoptosis and Improved Implant Osseointegration in Osteoporosis.
Topics: Animals; Apoptosis; Biocompatible Materials; Bone and Bones; Cell Differentiation; Cell Line; Delaye | 2020 |
Melatonin promotes bone marrow mesenchymal stem cell osteogenic differentiation and prevents osteoporosis development through modulating circ_0003865 that sponges miR-3653-3p.
Topics: Animals; Cell Cycle Proteins; Cell Differentiation; GPI-Linked Proteins; Melatonin; Mesenchymal Stem | 2021 |
The lncRNA H19/miR-541-3p/Wnt/β-catenin axis plays a vital role in melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells.
Topics: Adipogenesis; Animals; beta Catenin; Cell Differentiation; Cells, Cultured; Disease Models, Animal; | 2021 |
Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis.
Topics: Adult; Animals; Biomarkers; Calcitonin; Calcium; Case-Control Studies; Encephalomyelitis, Autoimmune | 2018 |
[Effects of aerobic exercise combined with melatonin on osteoporosis of type II diabetic rats].
Topics: Animals; Antioxidants; Bone Density; Calcium; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2017 |
Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats.
Topics: Alendronate; Animals; Bone Matrix; Female; Gastritis; Inflammation; Melatonin; Osteoporosis; Ovariec | 2019 |
MicroRNA-92b-5p modulates melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ICAM-1.
Topics: Bone Resorption; Cell Differentiation; Cell Line; Humans; Intercellular Adhesion Molecule-1; Melaton | 2019 |
Melatonin dietary supplement as an anti-aging therapy for age-related bone loss.
Topics: Aging; Animals; Antioxidants; Bone and Bones; Bone Density; Dietary Supplements; Disease Models, Ani | 2014 |
Melatonin suppresses autophagy in type 2 diabetic osteoporosis.
Topics: Animals; Autophagy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Male; MAP Ki | 2016 |
Melatonin Treatment Improves Mesenchymal Stem Cells Therapy by Preserving Stemness during Long-term In Vitro Expansion.
Topics: Animals; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Cell Transplantation; Ce | 2016 |
Pinealectomy affects bone mineral density and structure--an experimental study in sheep.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Disease Models, Animal; Female; Ilium; Melatonin | 2011 |
Changes in vascularity of cartilage endplate of degenerated intervertebral discs in response to melatonin administration in rats.
Topics: Animals; Bone Density; Cartilage; Disease Models, Animal; Free Radical Scavengers; Intervertebral Di | 2003 |
Evaluation of the relationship between inducible nitric oxide synthase (iNOS) activity and effects of melatonin in experimental osteoporosis in the rat.
Topics: Animals; Antioxidants; Apoptosis; Disease Models, Animal; Female; Growth Plate; Immunoenzyme Techniq | 2006 |
Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis.
Topics: Adipocytes; Animals; Cell Differentiation; Cell Line; Melatonin; Oleic Acid; Osteoblasts; Osteoporos | 2007 |
Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats.
Topics: Animals; Bone Density; Female; Lumbar Vertebrae; Melatonin; Osteoporosis; Ovariectomy; Rats; Rats, W | 2007 |
Benefits of sunlight: a bright spot for human health.
Topics: Female; Humans; Male; Melatonin; Neoplasms; Osteoporosis; Sunlight; Ultraviolet Rays; Vitamin D | 2008 |
The influence of pinealectomy and melatonin administration on the dynamic pattern of biochemical markers of bone metabolism in experimental osteoporosis in the rat.
Topics: Alkaline Phosphatase; Animals; Biomarkers; Bone and Bones; Collagen; Female; Melatonin; Osteoporosis | 2002 |